JPRN-UMIN000009311招募中2 期
The efficacy of fosaprepitant to the moderate emetic risk intravenous chemotherapy - The efficacy of fosaprepitant to the moderate emetic risk intravenous chemotherapy
Division of Clinical Oncology, Tohoku University Hospital0 个研究点目标入组 50 人开始时间: 2012年11月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Serious complications (e.g. severe liver disfunction or renal disfunction) 2)Patients with factors besides chemotherapy(e.g. brain tumor, passage disorder of digestive tract, active digestive ulcer, brain metastases) 3)Poorly controlled diabetes 4)Pregnant or lactating women or women of childbearing potential 5)Patients during pimozide administration 6)Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
已完成
2 期
Phase 2 study of efficacy and safety of fosaprepitant in patients with solid tumor receiving highly emetogenic chemotherapyPatients with solid tumor receiving highly emetogenic chemotherapy including cisplatin.JPRN-UMIN000012202Kyushu University40
已完成
2 期
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)Chemotherapy-induced Nausea and VomitingNCT01697579Merck Sharp & Dohme LLC240
终止
3 期
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)Chemotherapy-induced Nausea and VomitingNCT02519842Merck Sharp & Dohme LLC75
已完成
4 期
Effect of febuxostat on disease progression in patients of chronic kidney disease with high uric acid levels in the blood.CTRI/2014/08/004853Institute of Postgraduate Medical Education and Research Kolkata93
已完成
2 期
Optimal administration of fosaprepitant in patients with colon cancerColon CancerJPRN-UMIN000010181Hitachi General Hospital40